FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC
- Amanda Bridges
- May 28, 2021
- Drugs
- No Comments
On May 28, 2021, the Food and Drug Administration granted accelerated approval to sotorasib (Lumakras™, Amgen, Inc.), a RAS GTPase family inhibitor, for adult patients with KRAS G12C ‑mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA ‑approved test, who have received at least one prior systemic therapy. FDA also…